Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Viatris: 2021 Is Trough Year For Earnings But Revenues A Trickier Prospect
Company ‘Very, Very Pleased’ With Q1 Financials
May 11 2021
•
By
Dean Rudge
Viatris has “at this point” reaffirmed full-year 2021 guidance • Source: Shutterstock
More from Earnings
More from Business